HIGHLIGHTS
- who: Hideyuki Furumoto and collaborators from the Bethesda, MD, USA have published the paper: Optimal Light Dose for hEGFR-TargetedNear-Infrared Photoimmunotherapy, in the Journal: Cancers 2022, 4042 of /2022/
- what: The authors determined the of in based on comparison of the therapeutic and adverse effects.
SUMMARY
Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer therapy that selectively and locally destroys cancer cells. Unlike conventional therapies that usually induce apoptosis, NIR-PIT induces a rapid immunogenic cell death, resulting in the stimulation of the host's immune_response against the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.